IQVIQVIA
Is the price fair?
Undemanding: modest expectations priced in and cheap vs its sector.
Priced for ~0% a year FCF growth. The price demands less than its three-year revenue growth of 5% a year, expectations look modest.
In its normal range: P/E 32.3 vs a 35.9 median over 39 quarters (−10% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Unless marked, from derived, as of Mar 31, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What IQV's price assumes
IQVIA trades at 32.3× earnings against 35.2× for the median Diagnostics & Research name, cheaper than its own group.
Trailing P/E · Diagnostics & Research median 35.2 · cheaper than the typical name in its group
- Price / sales
- 1.68
Price / sales · today's price, trailing year to Mar 31, 2026
- Free cash flow yield
- 7.6%
Free cash flow yield · Diagnostics & Research median 3.7%
- Growth the price implies
- +0.16%
Growth the price implies · The price pays for +0.16% free cash flow growth a year for a decade; the business has delivered +12% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Mar 31, 2026
- 4.50
- EV / EBITtoday's price, trailing year to Mar 31, 2026
- 19.0
- EV / salestoday's price, trailing year to Mar 31, 2026
- 2.51
- Healthcare median P/E509 names
- 26.2
- Diagnostics & Research median P/E33 names
- 35.2
- Free cash flow, trailing twelve months
- $2.12B
- Market capitalisation
- $28.0B
- 3-year revenue growth
- +4.7%
- 3-year free cash flow growth
- +12%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $210.88 |
| Its own P/E history, median | $289.21 |
| Its own P/E history, upper quartile | $748.20 |
| 52-week range | $156.66 – $275.17 |
| Today | $259.96 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
The closest names by size in the same industry